Coherus BioSciences Inc (CHRS) Actualités

Form 8-K - Current report

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS...

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and...

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS...